Case report: Mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance

Journal of Hematology and Oncology

Volumn 9, Issue 1, 2016, Pages

  Chen, Kuo Hsing ^a,b   Yuan, Chang Tsu ^a   Tseng, Li Hui ^a   Shun, Chia Tung ^a,b,c   Yeh, Kun Huei ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Anti programmed death 1 antibody; Gastric cancer; Immunotherapy; Microsatellite stability; Mismatch repair deficiency; Mismatch repair proficiency

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PEMBROLIZUMAB; PERTUZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MICROSATELLITE DNA; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; EPIGASTRIC PAIN; ESOPHAGOGASTRODUODENOSCOPY; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MISMATCH REPAIR; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR RECURRENCE; TUMOR REGRESSION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; METABOLISM; PROGNOSIS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DNA MISMATCH REPAIR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84962431681     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-016-0259-0     Document Type: Article

References (25)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.
3. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-20.
4. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-9.
5. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-35.
6. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
7. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65.
8. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919-32.
9. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer discovery. 2015;5(1):43-51.
10. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol. 1994;145(1):148-56.
11. Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmoller P, Gutjahr T, Kaufmann M, Henkel T, Ruschoff J. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. Journal of clinical pathology. 2008;61(1):89-94.
12. Tsai JH, Lin YL, Cheng YC, Chen CC, Lin LI, Tseng LH, Cheng ML, Liau JY, Jeng YM. Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma. Modern pathology. 2015;28(2):268-78.
13. Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, Yang AG, Wen WH. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One. 2013;8(10):e76012.
14. Bang YJ, Shankaran V, Geva R, Yang AG, Wen WH. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol. 2015;33(suppl; abstr 4001).
15. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202-9.
16. Kim KJ, Jung HY, Oh MH, Cho H, Lee JH, Lee HJ, Jang SH, Lee MS. Loss of ARID1A expression in gastric cancer: correlation with mismatch repair deficiency and clinicopathologic features. Journal of gastric cancer. 2015;15(3):201-8.
17. van Grieken NC, Aoyama T, Chambers PA, Bottomley D, Ward LC, Inam I, Buffart TE, Das K, Lim T, Pang B. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. Br J Cancer. 2013;108(7):1495-501.
18. Wu MS, Lee CW, Shun CT, Wang HP, Lee WJ, Chang MC, Sheu JC, Lin JT. Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. Genes Chromosomes Cancer. 2000;27(4):403-11.
19. Simpson AJ, Caballero OL, Pena SD. Microsatellite instability as a tool for the classification of gastric cancer. Trends Mol Med. 2001;7(2):76-80.
20. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.
21. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, NY). 2015;348(6230):124-8.
22. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45(2):136-44.
23. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA oncology. 2015;1(9):1319-23.
24. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clinical cancer research. 2013;19(13):3462-73.
25. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clinical cancer research. 2012;18(6):1611-8.